LEO Pharma's Taclonex Topical Suspension Approved for Body Plaques

LEO Pharma Inc. announced the US Food and Drug Administration (FDA) approval of Taclonex (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% for the treatment of body plaque psoriasis. Taclonex® Topical Suspension is a first-line single treatment now indicated for both scalp and body plaque psoriasis for up to 8 weeks. In two Phase 3 clinical studies of more than 1,600 patients with psoriasis on the scalp, and one Phase 3 clinical study of over 1,100 patients with psoriasis on the body, a higher percentage of patients treated with Taclonex Topical Suspension achieved controlled disease than either monotherapies or vehicle used alone. In clinical trials, the most common adverse reactions that occurred in more than 1 percent of subjects treated with Taclonex Topical Suspension and at a rate higher than in subjects treated with vehicle were folliculitis and burning sensation of the skin.